Erschienen in:
Open Access
27.04.2021 | Correction
Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
verfasst von:
Shayma Kazmi, Debanjana Chatterjee, Dheeraj Raju, Rob Hauser, Peter A. Kaufman
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 2/2021
Einloggen, um Zugang zu erhalten
Excerpt
In the original publication, two values provided for landmark survival for patients treated with gemcitabine were incorrectly listed in the text. On page 562, paragraph 3, the text listed that “for TNBC: 50%, 31%, 20%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 3%, respectively”. The correct values should be “for TNBC: 50%, 31%, 11%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 7%, respectively”. The correct values are consistent with those listed in Table 2. …